Drugs / SYS6026
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07702656 | Jul 2026 → Sep 2028 expected | cervical intraepithelial neoplasia grade 2/3 | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-12 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - BIVALENT HPV mRNA THERAPEUTIC VACCINE (SYS6026) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-22 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - PHASE II CLINICAL TRIAL OF SYS6026 INJECTION FOR THE TREATMENT OF HPV TYPE 16- OR 18-RELATED CERVICAL HIGH-GRADE SQUAMOUS INTRAEPITHELIAL LESION OFFICIALLY INITIATED IN CHINA irasia.com ↗ |
| 2024-11-12 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | VOLUNTARY ANNOUNCEMENT - BIVALENT HPV mRNA THERAPEUTIC VACCINE (SYS6026) OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYS6026 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07702656 ↗ |
| Route | Subcutaneous | “SYS6026, dose1,subcutaneous injection, three primary immunizations and one booster” NCT07702656 ↗ |